Familial Adenomatous PolyposisPhase 2NCT04230499
Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
A Phase 2 study testing Encapsulated Rapamycin (eRapa) in people with Familial Adenomatous Polyposis, run by Rapamycin Holdings Inc. at 4 sites in United States.
Trial summary
Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Familial Adenomatous Polyposis
- What is being tested?
- Encapsulated Rapamycin (eRapa)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 4 sitesUnited States
- Study dates
- 18 Jan 2021to 22 May 2025
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Sign and date an informed consent form.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Male or female, age at least 18 years at the time of consent.
- Phenotypic familial adenomatous polyposis (FAP) with disease involvement of the colorectum by either genetic or clinical diagnosis: Adenomatous polyposis coli (APC) germline mutation with or without family history, or with greater than a cumulative lifetime history of (>) 100 adenomas in large intestine and a family history of FAP, or FAP phenotype post colectomy for polyposis with a family history of FAP. Minimum number of polyps required for enrollment is 10.
- Abilitiy to safely undergo endoscopy.
- Ability to take oral medication and be willing to adhere to the eRapa regimen.
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 12 weeks after the end of eRapa administration.
- A woman must agree not to breast feed or donate eggs (ova, oocytes) during the study and for a period of 12 weeks after the last administration of study drug.
Who cannot join
- Risk-reduction surgery (colectomy or partial colectomy) within the 12 months prior to screening.
- Use of non-steroidal anti-inflammatory drugs other than aspirin during the study. The use of 81 milligrams (mg) of aspirin a day or 650 mg of aspirin per week is allowed.
- Treatment with other FAP-directed drug therapy (including NSAID [Non-steroidal anti-inflammatory drug] drugs), unless completes a 4 week washout period prior to enrollment.
- Duodenum or colon/ rectum with high grade dysplasia or cancer on biopsy at screening.
- Duodenal or colorectal polyp > 1 centimeter (cm) not excised at the screening evaluation.
- Pregnancy or breast feeding.
Show all 15Show fewer
- Unable to provide consent or anticipated inability to attend appropriate follow-up visits.
- Serum creatinine or measured/ calculated creatinine clearance (or glomerular filtration rate [GFR]) > 1.5 x ULN OR < 30mL/min for participants with creatine levels > 1.5 x institutional ULN. Bilirubin ≥ 1.5 x ULN unless conjugated bilirubin ≤ ULN; alkaline phosphatase > 5 x ULN; ALT/AST > 2 x ULN.
- INR or PT or aPTT > 1.5 x institutional ULN unless the patient is receiving anticoagulant therapy as long as the PT or aPTT is within therapeutic range of intended use of anticoagulants.
- Proteinuria > 1+ on urinalysis or > 1g/24h on 24h urine.
- History of interstitial lung disease or non-infectious pneumonitis.
- Immunosuppressed state (e.g., HIV, use of chronic steroids), active, uncontrolled infection.
- On agents known to alter rapamycin metabolism significantly.
- Concurrent involvement in other clinical trials specifically evaluating chemoprevention in FAP.
- Patients with a colonic polyp burden too numerous to count.
Trial locations and contacts
4 sites in 1 country.
United States4 sites
Michigan Medicine
Ann Arbor, Michigan, 48109
Cleveland Clinic
Cleveland, Ohio, 44195
Ohio State University
Columbus, Ohio, 43210
UT Health
San Antonio, Texas, 78229
About this study
Official title: Phase IIa Trial of Encapsulated Rapamycin (eRapa) to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden.
Read the detailed description
Patients with FAP who are undergoing endoscopic surveillance will be given eRapa at one of three escalating doses/ schedules (0.5mg every other day, 0.5mg daily every other week, or 0.5mg daily) for 12 months with the aim of reducing polyp burden. Patients will serve as their own controls. Patients will be assessed with surveillance endoscopy at baseline, 6 months, and 12 months for change in polyp burden. Correlation between immune markers and clinical outcomes will be explored.
This is a Phase IIa trial which will enroll at approximately 6-8 sites within the United States that have specialty expertise in FAP treatment and surveillance. The trial is anticipated to last approximately 24 months for treatment and follow up.
The trial will enroll 30 patients with the genetic or clinical diagnosis of FAP. The clinical diagnosis includes individuals with 100 or more cumulative tubular adenomas throughout the colorectum. Patients must be undergoing surveillance for known FAP and can include those with intact colons as well as those who have undergone surgical therapy. For those patients who have undergone partial or total colectomy, they must have documented residual polyps in their rectum for which they are receiving active surveillance.
Once the recommended phase 2 dose (RP2D) is identified, subjects will undergo evaluation under fed and fasted states to determine the food effect on eRapa absorption.
- Conditions
- Familial Adenomatous Polyposis
- Being tested
- Encapsulated Rapamycin (eRapa)
- Medical subject headings
- Adenomatous Polyposis Coli
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Encapsulated Rapamycin (eRapa)Drug
Also called eRapa; Encapsulated sirolimus
eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1 | Experimental | Cohort 1 will receive 0.5mg of eRapa every other day. Receives: Drug: Encapsulated Rapamycin (eRapa) |
| Cohort 2 | Experimental | Cohort 2 will receive 0.5mg of eRapa daily with 7 days on therapy, followed by 7 days off therapy. Receives: Drug: Encapsulated Rapamycin (eRapa) |
| Cohort 3 | Experimental | Cohort 3 will receive 0.5 mg of eRapa daily. Receives: Drug: Encapsulated Rapamycin (eRapa) |
| Food Effect | Experimental | Upon identification of the RP2D, after a 2 week washout (14 days), subjects will be randomized into a fed and fasted (2 weeks - 14 days) two period cross over, with an intervening 2 week washout (14 days) for a total of 2 months (8 weeks). Receives: Drug: Encapsulated Rapamycin (eRapa) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change From Baseline in Colorectal Polyp Burden at Month 6
Colorectal polyp burden was assessed by colonoscopy at baseline and Month 6 (180 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible polyp was measured. Colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated as: (Month6polypburden-adjustedbaselinepolypburden)÷adjustedbaselinepolypburden × 100.
Measured: 6 months
Secondary outcomes (8)
Percent Change From Baseline in Colorectal Polyp Burden at Month 12
Colorectal polyp burden was assessed by colonoscopy at baseline and Month 12 (360 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible polyp was measured. Colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated as: [(Month 12 polyp burden - adjusted baseline polyp burden) ÷ adjusted baseline polyp burden] × 100.
Measured: 12 months.
Clinical Effect of eRapa on International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Stage.
The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) Familial Adenomatous Polyposis (FAP) Staging System is a validated clinical scoring system used to assess the severity of polyposis in patients with FAP. Staging is based on polyp number, size, endoscopic resectability, and the presence of advanced pathology. The scale consists of a single overall stage (0-4) and does not include subscale scores: Stage 0 = 0-10 polyps, all <5 mm; Stage 1 = 10-25 polyps, predominantly <5 mm, none >1 cm; Stage 2 = 10-25 polyps with ≥1 polyp >1 cm, all amenable to complete removal; Stage 3 = >25 polyps amenable to complete removal, an incompletely removed sessile polyp, or high-grade dysplasia; Stage 4 = high-grade dysplasia in an incompletely removed lesion and/or invasive colorectal cancer. Change from baseline was calculated as the difference in stage between baseline and post-treatment assessment.
Measured: Following patients out to 6 and 12 months.
Clinical Effect of eRapa on Spigelman Stage Score.
The Spigelman Staging System is a validated clinical scoring system used to assess the severity of duodenal polyposis in patients with Familial Adenomatous Polyposis (FAP). The score is based on four components evaluated during upper endoscopy: number of duodenal adenomas, size of the largest adenoma, histology, and degree of dysplasia. Points are assigned to each component and summed to generate a total score ranging from 0 to 12. The overall stage is classified as Stage 0 (0 points), Stage I (1-4 points), Stage II (5-6 points), Stage III (7-8 points), or Stage IV (9-12 points), with higher stages indicating more severe duodenal disease. The measure consists of a single overall stage and does not include subscale scores. Reported values represent absolute Spigelman stage at each assessment timepoint. Change from baseline was calculated as the difference in stage between baseline and post-treatment assessment.
Measured: Following patients out to 6 and 12 months.
Percent Change From Baseline in Duodenal Polyp Burden at Months 6 and 12
Duodenal polyp burden was assessed by gastroduodenoscopy at baseline and at Months 6 (180 days) and 12 (360 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible duodenal polyp was measured. Duodenal polyp burden was defined as the sum of the diameters of all eligible duodenal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated separately for the Month 6 and Month 12 assessments as: [(follow-up polyp burden - adjusted baseline polyp burden) ÷ adjusted baseline polyp burden] × 100.
Measured: Following patients out to 6 and 12 months.
Determine the Effect of Food on eRapa Absorption cMax
Cmax pharmacokinetic parameters to assess the effect of food on the bioavailability of the anticipated RP2D
Measured: 2 months
Determine the Effect of Food on eRapa Absorption AUC
AUC₀-∞ Pharmakinetic parameters to assess the effect of food on eRapa absorption
Measured: 2 months
Sum of Diameters of Eligible Colorectal Polyps at Baseline
Colorectal polyp burden was assessed by gastroduodenoscopy at baseline. Polyps measuring ≥3 mm were counted, and the diameter of each eligible colorectal polyp was measured. Baseline colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation.
Measured: baseline
Sum of Diameters of Eligible Duodenal Polyps at Baseline
Duodenal polyp burden was assessed by gastroduodenoscopy at baseline. Polyps measuring ≥3 mm were counted, and the diameter of each eligible duodenal polyp was measured. Baseline duodenal polyp burden was defined as the sum of the diameters of all eligible duodenal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation.
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jan 2020
- Study start18 Jan 2021
- Primary completion11 Dec 2024
- Study completion22 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Familial Adenomatous PolyposisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- Patients will receive one of three doses in a dose-escalating fashion. Cohort 1 will receive 0.5mg every other day, Cohort 2 will receive 0.5mg daily with 7 days on therapy followed by 7 days off therapy, and Cohort 3 will receive 0.5 mg daily. Patients will serve as their own control; no placebo will be given. Additionally, a subset of participants will be included in a randomized, balanced, single-schedule, two-treatment period (fed versus fasted) crossover study. Participants will receive eRapa under fed or fasted conditions in the first period, and then crossover to the other treatment (fed to fasted and vice versa) following a 2 week washout. Under this design, participants serve as their own control and will allow the assessment of the effect of food on the anticipated R2PD of eRapa
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rapamycin Holdings Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Cancer Insight, LLC, Biodexa Pharmaceuticals
- Responsible party
- Sponsor
- Investigators
- Gary Shangold, MD, Study director, Sponsor CMO
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04230499
- Sponsor's protocol ID
- EMT-FAP-001
- Status last verified
- Oct 2026
- First submitted
- 12 Jan 2020
- Last updated
- 22 Oct 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Stone JK, Mehta NA, Singh H, El-Matary W, Bernstein CN. Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome. Fam Cancer. 2023 Oct;22(4):413-422. doi: 10.1007/s10689-023-00334-3. Epub 2023 Apr 29.
PubMed 37119510
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase IIa Trial of Encapsulated Rapamycin (eRapa) to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
- ClinicalTrials.gov ID
- NCT04230499
- Acronym / sponsor ID
- EMT-FAP-001
- Conditions
- Familial Adenomatous Polyposis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Rapamycin Holdings Inc.Industry (pharma, biotech, devices)
- Collaborators
- Cancer Insight, LLC, Biodexa Pharmaceuticals
- Study start
- 18 Jan 2021 (actual)
- Primary completion
- 11 Dec 2024 (actual)
- Study completion
- 22 May 2025 (actual)
- First posted
- 18 Jan 2020 (actual)
- Results
- Posted 22 Oct 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden.
Detailed description
Patients with FAP who are undergoing endoscopic surveillance will be given eRapa at one of three escalating doses/ schedules (0.5mg every other day, 0.5mg daily every other week, or 0.5mg daily) for 12 months with the aim of reducing polyp burden. Patients will serve as their own controls. Patients will be assessed with surveillance endoscopy at baseline, 6 months, and 12 months for change in polyp burden. Correlation between immune markers and clinical outcomes will be explored.
This is a Phase IIa trial which will enroll at approximately 6-8 sites within the United States that have specialty expertise in FAP treatment and surveillance. The trial is anticipated to last approximately 24 months for treatment and follow up.
The trial will enroll 30 patients with the genetic or clinical diagnosis of FAP. The clinical diagnosis includes individuals with 100 or more cumulative tubular adenomas throughout the colorectum. Patients must be undergoing surveillance for known FAP and can include those with intact colons as well as those who have undergone surgical therapy. For those patients who have undergone partial or total colectomy, they must have documented residual polyps in their rectum for which they are receiving active surveillance.
Once the recommended phase 2 dose (RP2D) is identified, subjects will undergo evaluation under fed and fasted states to determine the food effect on eRapa absorption.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- Patients will receive one of three doses in a dose-escalating fashion. Cohort 1 will receive 0.5mg every other day, Cohort 2 will receive 0.5mg daily with 7 days on therapy followed by 7 days off therapy, and Cohort 3 will receive 0.5 mg daily. Patients will serve as their own control; no placebo will be given. Additionally, a subset of participants will be included in a randomized, balanced, single-schedule, two-treatment period (fed versus fasted) crossover study. Participants will receive eRapa under fed or fasted conditions in the first period, and then crossover to the other treatment (fed to fasted and vice versa) following a 2 week washout. Under this design, participants serve as their own control and will allow the assessment of the effect of food on the anticipated R2PD of eRapa
| Arm | Type | Receives |
|---|---|---|
| Cohort 1 | Experimental | Drug: Encapsulated Rapamycin (eRapa)Cohort 1 will receive 0.5mg of eRapa every other day. |
| Cohort 2 | Experimental | Drug: Encapsulated Rapamycin (eRapa)Cohort 2 will receive 0.5mg of eRapa daily with 7 days on therapy, followed by 7 days off therapy. |
| Cohort 3 | Experimental | Drug: Encapsulated Rapamycin (eRapa)Cohort 3 will receive 0.5 mg of eRapa daily. |
| Food Effect | Experimental | Drug: Encapsulated Rapamycin (eRapa)Upon identification of the RP2D, after a 2 week washout (14 days), subjects will be randomized into a fed and fasted (2 weeks - 14 days) two period cross over, with an intervening 2 week washout (14 days) for a total of 2 months (8 weeks). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Sign and date an informed consent form.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Male or female, age at least 18 years at the time of consent.
- Phenotypic familial adenomatous polyposis (FAP) with disease involvement of the colorectum by either genetic or clinical diagnosis: Adenomatous polyposis coli (APC) germline mutation with or without family history, or with greater than a cumulative lifetime history of (>) 100 adenomas in large intestine and a family history of FAP, or FAP phenotype post colectomy for polyposis with a family history of FAP. Minimum number of polyps required for enrollment is 10.
- Abilitiy to safely undergo endoscopy.
Key exclusion criteria (15 listed)
- Risk-reduction surgery (colectomy or partial colectomy) within the 12 months prior to screening.
- Use of non-steroidal anti-inflammatory drugs other than aspirin during the study. The use of 81 milligrams (mg) of aspirin a day or 650 mg of aspirin per week is allowed.
- Treatment with other FAP-directed drug therapy (including NSAID [Non-steroidal anti-inflammatory drug] drugs), unless completes a 4 week washout period prior to enrollment.
- Duodenum or colon/ rectum with high grade dysplasia or cancer on biopsy at screening.
- Duodenal or colorectal polyp > 1 centimeter (cm) not excised at the screening evaluation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Encapsulated Rapamycin (eRapa)Also: eRapa; Encapsulated sirolimuseRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally. | Drug | Cohort 1, Cohort 2, Cohort 3, Food Effect |
Primary outcome
Percent Change From Baseline in Colorectal Polyp Burden at Month 6
Time frame: 6 months
Colorectal polyp burden was assessed by colonoscopy at baseline and Month 6 (180 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible polyp was measured. Colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated as: (Month6polypburden-adjustedbaselinepolypburden)÷adjustedbaselinepolypburden × 100.
8 secondary outcomes
Percent Change From Baseline in Colorectal Polyp Burden at Month 12
Time frame: 12 months.
Clinical Effect of eRapa on International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Stage.
Time frame: Following patients out to 6 and 12 months.
Clinical Effect of eRapa on Spigelman Stage Score.
Time frame: Following patients out to 6 and 12 months.
Percent Change From Baseline in Duodenal Polyp Burden at Months 6 and 12
Time frame: Following patients out to 6 and 12 months.
Determine the Effect of Food on eRapa Absorption cMax
Time frame: 2 months
Determine the Effect of Food on eRapa Absorption AUC
Time frame: 2 months
Sum of Diameters of Eligible Colorectal Polyps at Baseline
Time frame: baseline
Sum of Diameters of Eligible Duodenal Polyps at Baseline
Time frame: baseline
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37119510Stone JK, Mehta NA, Singh H, El-Matary W, Bernstein CN. Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome. Fam Cancer. 2023 Oct;22(4):413-422. doi: 10.1007/s10689-023-00334-3. Epub 2023 Apr 29.
Related trials for Familial Adenomatous Polyposis
RecruitingPhase 1
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
Colorectal Adenomatous Polyp, Colorectal Carcinoma
RecruitingPhase 1/2
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Cancer, Colorectal Cancer
Enrolling by invitation
Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis
FAP, Familial Adenomatous Polyposis
RecruitingPhase 2
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
Colorectal Carcinoma, Familial Adenomatous Polyposis
Not yet recruitingPhase 1
A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).
Familial Adenomatous Polyposis (FAP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gary Shangold, MD study director
Sponsor CMO
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Encapsulated Rapamycin (eRapa) in people with Familial Adenomatous Polyposis, run by Rapamycin Holdings Inc. at 4 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Oct 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent Change From Baseline in Colorectal Polyp Burden at Month 6 (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04230499, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.